C. Portera

发表

FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer

N. Gusani, W. El-Deiry, A. Ashkenazi, 2013, Cancer biology & therapy.

The heart of the matter.

S. Swain, C. Portera, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.

Z. Wainberg, A. Ashkenazi, W. Messersmith, 2013, Clinical colorectal cancer.

DMD053926 2104..2113

A. Tolcher, W. Fairbrother, E. Kadel, 2013 .

A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors

A. Tolcher, F. Peale, K. Papadopoulos, 2016, Clinical Cancer Research.

Evaluation of lymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer.

S. Hewitt, S. Swain, P. Levine, 2012, Clinical breast cancer.

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

L. Amler, H. Stern, J. Baranda, 2012, Cancer investigation.

Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC).

J. Bendell, A. Ashkenazi, M. Kozloff, 2012 .

Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC).

Z. Wainberg, A. Ashkenazi, W. Messersmith, 2011 .

Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months

K. Saini, E. de Azambuja, M. Saini, 2020, Oncology and Therapy.

Optic neuropathy from metastatic squamous cell carcinoma of the cervix: an unusual CNS presentation.

D. Armstrong, R. Gottesman, F. Asrari, 2006, Gynecologic oncology.

Phase Ib study of drozitumab combined with cetuximab (CET) plus irinotecan (IRI) or with FOLFIRI ± bevacizumab (BV) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC).

A. Ashkenazi, A. Baron, C. O’Bryant, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

S. Steinberg, S. Swain, Sherry X. Yang, 2008, Clinical Cancer Research.

CardiacToxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2^ Positive Metastatic Breast Cancer

S. Steinberg, S. Swain, Sherry X. Yang, 2008 .

Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma.

A. Tolcher, F. Peale, K. Papadopoulos, 2013 .

Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist

A. Tolcher, W. Fairbrother, E. Kadel, 2013, Drug Metabolism and Disposition.

Skin and subcutaneous tissue disorders (SSTDs) in patients (pts) with HER2-positive metastatic breast cancer (MBC) in the phase III trial CLEOPATRA of pertuzumab or placebo with trastuzumab and docetaxel.

S. Swain, D. Miles, A. Knott, 2015 .